The impact of <em>KRAS</em> mutational status on patient-reported outcomes in advanced non-small-cell lung cancer: a cross sectional study in France and Germany CONCLUSION: HRQoL was broadly similar across KRAS G12C, non-G12C, and WT … ← Medicare's New Mandatory Bundled-Payment Program - Are We Ready for TEAM? The prognostic value of the Dandel's index in patients undergoing tricuspid transcatheter edge-to-edge repair →